Struggling Ottawa medical device firm Annidis (TSX-V: RHA) said it shipped 15 units of its eye-care imaging technology to its Chinese distribution partner and major shareholder during the second quarter, leading to a dramatic jump in revenues.
The company recorded $786,279 in revenue, up 476 per cent from a year earlier when it failed to make a sale in the quarter.
Annidis also slashed its operating expenses by 27 per cent in the quarter by reducing R&D spending. Combined with the higher sales, the company reduced its net loss to $698,261 for the quarter, an improvement on the $1.29 million loss it recorded a year earlier.
OBJ360 (Sponsored)
BAE Systems’ talent, innovation generating Canadian growth and security
BAE Systems has played a vital role in the Canadian defence and security industrial base for more than a century. Since 1911, it has worked with the Canadian Armed Forces
Care, Serve, & Give: Dr. Helen Tang is redefining what it means to lead with purpose
Dr. Helen Tang is a dynamic and multifaceted leader whose passion for community and philanthropy is at the heart of everything she does. As a devoted mother of two and
Earlier this year, the company’s auditors expressed concern about the firm’s ability to continue operating amid its mounting debt.
Annidis’ stock price was flat at one cent on the TSX Venture Exchange on Monday.
